CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has announced the appointment of two industry thought-leaders to its senior team, as it continues its impressive global growth throughout North America, Europe and Asia Pacific.
Richard Davies joins as VP, Solutions Expert, and Suzanne Lukac as Senior Account Director.
Suzanne Lukac joins the company from Merck, where she was previously Director for Clinical Operations, Global RBM Implementation, with over 20 years’ proven practical experience in the pharmaceutical industry and brings unrivalled hands-on experience in the tactical implementation of RBM to her new role, along with a thorough understanding of the implementation process and beyond.
Based in the US, Suzanne will take on a global role with responsibility for managing both enterprise-level clients and individual study engagements, taking primary accountability for ensuring client success, and working with customers to lay the foundations for a successful RBM implementation. Suzanne will also lead the development and delivery of consultative services covering RBM methodology as well as working closely with the product team advising on enhancements to CluePoints’ RBM platform.
Previously at OmniComm Systems as Executive Director of Business Solutions, Richard brings a wealth of technical expertise to his new role, with over 20 years’ experience in the industry.Richard has worked with electronic data capture technology since its introduction and as such, has a real in-depth understanding of technology and how it can be utilised within clinical trials. Based in Europe but with a global role, Richard will be the go-to expert on CluePoints’ RBM technology. He will be responsible for supporting the product development and adoption processes for CluePoints’ solutions to worldwide pharmaceutical and biotechnology companies and CROs, and will act as a commercial product expert for all elements of the software product.
Commenting on these appointments, Francois Torche, CEO at CluePoints comments, “Richard and Suzanne are recognized industry experts. As we continue with our ambitious growth plans, their wealth of knowledge will be fundamental to our clients’success and will drive thought-leadership on behalf of CluePoints. I am delighted that Suzanne and Richard are joining the team as subject matter experts in their respective functional areas.”
Having already established itself as the leading provider of RBM technology and are finalist’s in the 2018 Scrip Awards for the Best Technological Development in Clinical Trials – Tech Sponsor-Focused Category, this latest announcement cements CluePoints’ ambitious plans to continue its global expansion. For further information on CluePoints’ solutions, please visit www.cluepoints.com
CluePoints® is a Risk-Based Monitoring and Central Statistical Monitoring solution that has been designed and perfected over the last 15 years. It employs unique statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the ICH, FDA, and EMA, CluePoints® is deployed to support traditional on-site monitoring, medical review and to drive a Risk-Based Monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.